Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Isoray Inc (ISR)

Isoray Inc (ISR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine

Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting,...

ISR : 0.3840 (+0.03%)
ISORAY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Isoray, Inc - ISR

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Isoray, Inc (“the Company”) (NYSE: ISR)...

ISR : 0.3840 (+0.03%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TALO, ISR, FCRD, SESN

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TALO : 11.81 (-0.76%)
ISR : 0.3840 (+0.03%)
FCRD : 4.54 (-3.61%)
SESN : 12.5760 (+7.29%)
Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT

Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, and Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based...

ISR : 0.3840 (+0.03%)
ISR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Isoray, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Isoray, Inc. (NYSE: ISR) and Viewpoint Molecular Targeting, Inc. is fair to Isoray shareholders.

ISR : 0.3840 (+0.03%)
Inflation Report Due in Canada Next Week

Monday U.S. Economic Lookahead NAHB home builders' index (Sept.) Featured Earnings Autozone ...

AZO : 2,828.27 (-1.45%)
NEOG : 15.19 (+0.40%)
APOG : 62.14 (+0.89%)
SFIX : 3.89 (-5.12%)
ISR : 0.3840 (+0.03%)
GIS : 62.87 (-0.47%)
LEN : 143.52 (-0.06%)
TCOM : 49.63 (+4.02%)
COST : 858.12 (-0.14%)
ACN : 305.94 (+0.69%)
FDX : 293.16 (-1.70%)
INM : 0.2558 (+3.23%)
Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference

RICHLAND, Wash., June 21, 2022 (GLOBE NEWSWIRE) -- The growing body of information regarding Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating...

ISR : 0.3840 (+0.03%)
Isoray To Host Lunch Symposium At American Brachytherapy Society’s Annual Conference

RICHLAND, Wash., June 15, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy,...

ISR : 0.3840 (+0.03%)
Isoray Announces Record Third Quarter Fiscal 2022 Financial Results

Revenue Increased 12% Year-Over-YearRecord Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, Wash., May 10, 2022 (GLOBE...

ISR : 0.3840 (+0.03%)
Isoray To Announce Third Quarter Fiscal 2022 Financial Results on May 10, 2022

Conference Call is Tuesday, May 10, 2022 at 4:30 p.m. ET/1:30 p.m. ...

ISR : 0.3840 (+0.03%)

Barchart Exclusives

The Spring Doldrums in The Gold Market May Be Changing Soon
Over the past five years, data shows distinct patterns in the seasonality of gold prices. September has consistently been weak, with prices often closing lower than they opened, suggesting a decrease in market confidence or a shift in investment focus. In contrast, due to increased buying, July has shown a higher probability of gold prices closing above their opening mark. Are the Spring doldrums in gold prices ready to change to higher prices? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar